Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBL 514

X
Drug Profile

CBL 514

Alternative Names: CBL-514

Latest Information Update: 17 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Caliway Biopharmaceuticals Australia
  • Class Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; Lipolysis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adiposis dolorosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adiposis dolorosa
  • Phase II Cellulite; Obesity; Subcutaneous fat disorders

Most Recent Events

  • 03 Sep 2024 Caliway Biopharmaceuticals initiates a phase II trial for Adiposis dolorosa in USA (SC) (NCT06303570)
  • 03 Sep 2024 Phase-III clinical trials in Adiposis dolorosa in USA (SC)
  • 03 Sep 2024 Caliway Biopharmaceuticals intends to submit IND application for a phase III pivotal trial for Adiposis dolorosa

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top